Literature DB >> 29090234

Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.

Reza Torshizi1, Ehsan Ghayour Karimani2, Kobra Etminani3, Mohammad Mehdi Akbarin4, Khadijeh Jamialahmadi5,6, Abbas Shirdel7, Hossein Rahimi7, Abolghasem Allahyari8, Amin Golabpour3, Houshang Rafatpanah4.   

Abstract

BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is caused by human T-cell lymphotropic virus type-1 (HTLV-1). HTLV-1 oncogenes can induce malignancy through controlled gene expression of cell cycle checkpoints in the host cell. HTLV-I genes play a pivotal role in overriding cell cycle checkpoints and deregulate cellular division. In this study, we aimed to determine and compare the HTLV-1 proviral load and the gene expression levels of cyclin-dependent kinase-2 (CDK2), CDK4, p53, and retinoblastoma (Rb) in ATLL and carrier groups.
METHODS: A total of twenty-five ATLL patients (12 females and 13 males) and 21 asymptomatic carriers (10 females and 11 males) were included in this study. TaqMan real-time polymerase chain reaction assay was used for evaluation of proviral load and gene expression levels of CDK2, CDK4, p53, and Rb. Statistical analysis was used to compare proviral load and gene expression levels between two groups, using SPSS version 18.
RESULTS: The mean scores of the HTLV-1 proviral load in the ATLL patients and healthy carriers were 13067.20±6400.41 and 345.79±78.80 copies/104 cells, respectively (P=0.000). There was a significant correlation between the gene expression levels of CDK2 and CDK4 (P=0.01) in the ATLL group.
CONCLUSION: Our findings demonstrated a significant difference between the ATLL patients and healthy carriers regarding the rate of proviral load and the gene expression levels of p53 and CDK4; accordingly, proviral load and expression levels of these genes may be useful in the assessment of disease progression and prediction of HTLV-1 infection outcomes.

Entities:  

Keywords:  Adult T-cell leukemia/ lymphoma; CDKs; HTLV-I; Retinoblastoma; p53

Year:  2017        PMID: 29090234      PMCID: PMC5643448     

Source DB:  PubMed          Journal:  Rep Biochem Mol Biol        ISSN: 2322-3480


  30 in total

1.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Authors:  Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless
Journal:  J Natl Cancer Inst       Date:  2012-02-01       Impact factor: 13.506

2.  Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.

Authors:  Masako Iwanaga; Toshiki Watanabe; Atae Utsunomiya; Akihiko Okayama; Kaoru Uchimaru; Ki-Ryang Koh; Masao Ogata; Hiroshi Kikuchi; Yasuko Sagara; Kimiharu Uozumi; Manabu Mochizuki; Kunihiro Tsukasaki; Yoshio Saburi; Masaomi Yamamura; Junji Tanaka; Yukiyoshi Moriuchi; Shigeo Hino; Shimeru Kamihira; Kazunari Yamaguchi
Journal:  Blood       Date:  2010-05-06       Impact factor: 22.113

3.  The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

Authors:  Isabell Witzel; Volkmar Müller
Journal:  Breast Care (Basel)       Date:  2016-06-22       Impact factor: 2.860

4.  Stimulation of cyclin-dependent kinase activity and G1- to S-phase transition in human lymphocytes by the human T-cell leukemia/lymphotropic virus type 1 Tax protein.

Authors:  I Schmitt; O Rosin; P Rohwer; M Gossen; R Grassmann
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.

Authors:  Hongjun Lv; Rui Liu; Jiao Fu; Qi Yang; Jing Shi; Pu Chen; Meiju Ji; Bingyin Shi; Peng Hou
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis.

Authors:  Priya Kannian; Patrick L Green
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

Review 7.  HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.

Authors:  Chou-Zen Giam; Oliver John Semmes
Journal:  Viruses       Date:  2016-06-16       Impact factor: 5.048

8.  The double benefit of Spalax p53: surviving underground hypoxia while defying lung cancer cells in vitro via autophagy and caspase-dependent cell death.

Authors:  Martin Ellis; Orly Stern; Osnat Ashur-Fabian
Journal:  Oncotarget       Date:  2016-09-27

9.  Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers.

Authors:  Mohammad Mehdi Akbarin; Hossein Rahimi; Tahereh Hassannia; Ghazaleh Shoja Razavi; Faezeh Sabet; Abbas Shirdel
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

10.  Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.

Authors:  Gary Beale; Emma J Haagensen; Huw D Thomas; Lan-Zhen Wang; Charlotte H Revill; Sara L Payne; Bernard T Golding; Ian R Hardcastle; David R Newell; Roger J Griffin; Celine Cano
Journal:  Br J Cancer       Date:  2016-08-16       Impact factor: 7.640

View more
  2 in total

1.  TAX and HBZ: hFc Ɣ 1 proteins as targets for passive immunotherapy.

Authors:  Mohammad Mehdi Akbarin; Houshang Rafatpanah; Saman Soleimanpour; Abbas Ali Amini; Amirali Arian; Arman Mosavat; Seyed Abdolrahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

Review 2.  Evaluation of Couple's Sexual Function after Childbirth with the Biopsychosocial Model: A Systematic Review of Systematic Reviews and Meta-Analysis.

Authors:  Saiedeh Saiedeh Hajimirzaie; Najmeh Tehranian; Fatemeh Razavinia; Ahmad Khosravi; Afsaneh Keramat; Arezoo Haseli; Mehdi Mirzaii; Seyed Abbas Mousavi
Journal:  Iran J Nurs Midwifery Res       Date:  2021-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.